COVID-19 drug targets and cell-based assays
Posted: 30 March 2021 | Alp Tegin Sahin (Kadir Has University), Sheraz Gul (Fraunhofer Institute) | No comments yet
The length of time between the administration of a COVID-19 vaccine and evidence of a robust immune response to Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) means that treatments are still required. In this article, Sheraz Gul and Alp Tegin Sahin explore the various therapeutic targets that have been identified to combat COVID-19 and the assays used to reveal the most promising drug candidates.
By the beginning of March 2021, over 115 million cases and 2.5 million COVID-19 related deaths were reported, according to the Center for Systems Science and Engineering at Johns Hopkins University. Europe is now past the second COVID-19 peak, with the European Centre for Disease Prevention and Control recording over 20 million cases and 500,000 deaths so far.
Related topics
Assays, Cell-based assays, Molecular Targets, Screening
Related conditions
Covid-19, Hepatitis C, Middle East Respiratory Syndrome (MERS)
Related organisations
Johns Hopkins University, US Food and Drug Administration (FDA)
